MiNK Therapeutics (NASDAQ:INKT) Shares Down 1.6% - Time to Sell?

Key Points

• MiNK Therapeutics shares fell 1.6% to $11.45, with trading volume up 45% from the average session. The company has a market capitalization of approximately $58.4 million.
• Analyst sentiment is mixed, resulting in a consensus “Hold” rating; the consensus price target is $35, including HC Wainwright’s “Buy” rating and $35 target.
• MiNK reported a quarterly loss of $0.62 per share, slightly worse than analysts’ expected loss of $0.60, while institutional investors own only 2.87% of the stock.

MiNK Therapeutics, Inc. (NASDAQ:INKT - Get Free Report) shares fell 1.6% during trading on Tuesday . The company traded as low as $11.45 and last traded at $11.45. Approximately 11,019 shares were traded during mid-day trading, an increase of 45% from the average session volume of 7,582 shares. The stock had previously closed at $11.64.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. HC Wainwright reaffirmed a "buy" rating and issued a $35.00 price objective on shares of MiNK Therapeutics in a research note on Monday, May 18th. Zacks Research downgraded MiNK Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, August 12th. Wall Street Zen raised shares of MiNK Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, May 16th. Finally, Weiss Ratings upgraded shares of MiNK Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Monday, July 6th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, MiNK Therapeutics currently has a consensus rating of "Hold" and a consensus price target of $35.00.

MiNK Therapeutics Trading Down 1.6%

The company has a market cap of $58.40 million, a PE ratio of -4.77 and a beta of 0.49. The business's 50 day moving average is $11.17 and its two-hundred day moving average is $11.22.

MiNK Therapeutics (NASDAQ:INKT - Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.02). As a group, equities research analysts predict that MiNK Therapeutics, Inc. will post -2.48 EPS for the current fiscal year.

Institutional Trading of MiNK Therapeutics

An institutional investor recently bought a new position in MiNK Therapeutics stock. DRW Securities LLC bought a new stake in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 25,677 shares of the company's stock, valued at approximately $286,000. DRW Securities LLC owned 0.55% of MiNK Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 2.87% of the company's stock.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company's proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK's preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.